A meta-analysis of smoking status on clinical outcomes of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor.
Yoshikazu Hasegawa
No relevant relationships to disclose
Masahiko Ando
No relevant relationships to disclose
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
Satomi Yamamoto
No relevant relationships to disclose
Shun-ichi Isa
No relevant relationships to disclose
Hideo Saka
Honoraria - Chugai Pharma; Lilly
Research Funding - AstraZeneca; Chugai Pharma; Lilly
Akihito Kubo
Honoraria - Chugai Pharma
Tomoya Kawaguchi
Honoraria - AstraZeneca; Chugai Pharma
Minoru Takada
No relevant relationships to disclose
Takayasu Kurata
Honoraria - AstraZeneca
Sai-Hong Ignatius Ou
No relevant relationships to disclose